
Adult Immunization
Latest News

FDA Expands Approval of Flibanserin for Hypoactive Sexual Desire Disorder to Women Younger Than 65 Years

Primary Care Physician Kevin Hatfield, MD, on Barriers to Daily Oral PrEP Adherence

FDA Clears Prescription Digital Therapeutic LumosityRx for Adults with ADHD

Alzheimer Diseae Drug Development Shifts as Tau Antibody Research Falters

Large National Claims Analysis Underscores Gap Between CGM Eligibility and Real-World Use in Diabetes Care
Shorts










Latest Videos
Podcasts
Screening
Continuing Medical Education
All News

Phase 3 results showed durable conversion benefits with a favorable safety profile, informing real-world management of acute PSVT outside of emergency settings.

A population-based study finds stimulant prescribing accelerated after 2020, with the largest increases among adults and women.

Zolifodacin is a single-dose oral treatment option for uncomplicated urogenital gonorrhea and one of the first new classes of drugs for the disease in 20 years.

A new review examines whether neuromodulation techniques may help address excessive daytime sleepiness across neurologic and psychiatric conditions.

Findings highlight an AI-based machine-learning approach designed to work around incomplete diagnostic labeling in Alzheimer disease using routine clinical data.

Your daily dose of the clinical news you may have missed.

Gepotidacin becomes the first new oral antibiotic for gonorrhea in over 30 years, offering hope for effective treatment options.

Both doses of the GLP-1, GIP, glucagon triple agonist (9- and 12-mg) met all primary and key secondary endpoints and reduced CV risk factors as well, Eli Lilly said.

Two global phase 3 trials found rocatinlimab significantly improved EASI-75 and vIGA-AD outcomes at 24 weeks in people with moderate-to-severe AD with acceptable safety.





























































































































































































































































































